ENZY Stock Overview
Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Enzymatica AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr3.25 |
52 Week High | kr4.43 |
52 Week Low | kr2.10 |
Beta | -0.072 |
1 Month Change | 6.38% |
3 Month Change | -17.62% |
1 Year Change | 16.07% |
3 Year Change | -69.51% |
5 Year Change | 44.44% |
Change since IPO | -56.08% |
Recent News & Updates
Recent updates
Is Enzymatica (STO:ENZY) Using Too Much Debt?
Jul 22Is Enzymatica (STO:ENZY) Weighed On By Its Debt Load?
Feb 18Estimating The Fair Value Of Enzymatica AB (STO:ENZY)
Jan 12Things Look Grim For Enzymatica AB (STO:ENZY) After Today's Downgrade
Jul 20Revenue Downgrade: Here's What Analysts Forecast For Enzymatica AB (STO:ENZY)
May 02Enzymatica AB (STO:ENZY) Analysts Just Cut Their EPS Forecasts
Mar 25Insider Buying: The Enzymatica AB (STO:ENZY) Director Just Bought kr102k Worth Of Shares
Mar 16Enzymatica AB (STO:ENZY) Is About To Turn The Corner
Mar 07Is Enzymatica AB's (STO:ENZY) Shareholder Ownership Skewed Towards Insiders?
Jan 23A Look At The Intrinsic Value Of Enzymatica AB (STO:ENZY)
Jan 02Trade Alert: The Independent Director Of Enzymatica AB (STO:ENZY), Louise Nicolin, Has Just Spent kr483k Buying 104% More Shares
Dec 15Shareholder Returns
ENZY | SE Pharmaceuticals | SE Market | |
---|---|---|---|
7D | 1.6% | 3.0% | 1.9% |
1Y | 16.1% | 81.6% | 17.1% |
Return vs Industry: ENZY underperformed the Swedish Pharmaceuticals industry which returned 81.6% over the past year.
Return vs Market: ENZY matched the Swedish Market which returned 17.1% over the past year.
Price Volatility
ENZY volatility | |
---|---|
ENZY Average Weekly Movement | 7.8% |
Pharmaceuticals Industry Average Movement | 6.6% |
Market Average Movement | 6.1% |
10% most volatile stocks in SE Market | 12.9% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: ENZY has not had significant price volatility in the past 3 months.
Volatility Over Time: ENZY's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 18 | Claus Egstrand | https://www.enzymatica.se |
Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company’s product includes ColdZyme, a mouth spray that prevents common cold and reduces the duration of illness. It also provides enzyme formulations.
Enzymatica AB (publ) Fundamentals Summary
ENZY fundamental statistics | |
---|---|
Market cap | kr533.83m |
Earnings (TTM) | -kr49.73m |
Revenue (TTM) | kr50.90m |
10.5x
P/S Ratio-10.7x
P/E RatioIs ENZY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ENZY income statement (TTM) | |
---|---|
Revenue | kr50.90m |
Cost of Revenue | kr19.04m |
Gross Profit | kr31.86m |
Other Expenses | kr81.59m |
Earnings | -kr49.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 09, 2024
Earnings per share (EPS) | -0.30 |
Gross Margin | 62.59% |
Net Profit Margin | -97.69% |
Debt/Equity Ratio | 34.1% |
How did ENZY perform over the long term?
See historical performance and comparison